drug
(abacavir sulfate + dolutegravir sodium + lamivudine)
Marketedupdated 5mo agoby ViiV Healthcare Company
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(1)
Trials studying (abacavir sulfate + dolutegravir sodium + lamivudine)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 15, 2026
65 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jun 8, 2030patentUS 9242986*PED3.7y
- Jun 8, 2030patentUS 9242986*PED3.7y
- Dec 8, 2029compositionUS 92429863.2y
- Dec 8, 2029compositionUS 92429863.2y
- Apr 5, 2028patentUS 8129385*PED1.5y
- Apr 5, 2028patentUS 8129385*PED1.5y
- Oct 5, 2027compositionUS 8129385359d
- Oct 5, 2027compositionUS 8129385359d
FDA exclusivities (4)
- Dec 15, 2026PEDPediatric (6mo bonus)65d
- Dec 15, 2026PEDPediatric (6mo bonus)65d
- Jun 15, 2026M-294Method (3y)
- Jun 15, 2026NPPNew Product (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 49m ago
Found something off?
comments(0)
5-min edit window · permanent after that